SK5422003A3 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders Download PDF

Info

Publication number
SK5422003A3
SK5422003A3 SK542-2003A SK5422003A SK5422003A3 SK 5422003 A3 SK5422003 A3 SK 5422003A3 SK 5422003 A SK5422003 A SK 5422003A SK 5422003 A3 SK5422003 A3 SK 5422003A3
Authority
SK
Slovakia
Prior art keywords
anxiety disorders
norepinephrine uptake
tomoxetine
uptake inhibitor
dsm
Prior art date
Application number
SK542-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Holly Read Thomasson
David Michelson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SK5422003A3 publication Critical patent/SK5422003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SK542-2003A 2000-11-15 2001-11-06 Treatment of anxiety disorders SK5422003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
SK5422003A3 true SK5422003A3 (en) 2003-12-02

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
SK542-2003A SK5422003A3 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Country Status (16)

Country Link
EP (1) EP1395253A2 (ko)
JP (1) JP2004529073A (ko)
KR (1) KR20030051812A (ko)
CN (1) CN1822825A (ko)
AU (1) AU2002217757A1 (ko)
BR (1) BR0115301A (ko)
CA (1) CA2426069A1 (ko)
CZ (1) CZ20031339A3 (ko)
EA (1) EA200300567A1 (ko)
HR (1) HRP20030384A2 (ko)
IL (1) IL155874A0 (ko)
MX (1) MXPA03004190A (ko)
NO (1) NO20032156L (ko)
PL (1) PL366119A1 (ko)
SK (1) SK5422003A3 (ko)
WO (1) WO2002040006A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070457A1 (en) * 2001-03-06 2002-09-12 Eli Lilly And Company Inhibitor of monoamine uptake
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
EP2234960A2 (en) 2008-01-09 2010-10-06 Mayo Foundation for Medical Education and Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
EA202192084A1 (ru) * 2019-02-01 2021-10-20 ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи. Композиции и способы для лечения связанных с тревожностью нарушений

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
PT1459750E (pt) * 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes

Also Published As

Publication number Publication date
WO2002040006A2 (en) 2002-05-23
MXPA03004190A (es) 2003-09-22
NO20032156D0 (no) 2003-05-13
CZ20031339A3 (cs) 2003-10-15
IL155874A0 (en) 2003-12-23
AU2002217757A1 (en) 2002-05-27
BR0115301A (pt) 2004-12-14
CN1822825A (zh) 2006-08-23
NO20032156L (no) 2003-05-13
CA2426069A1 (en) 2002-05-23
EA200300567A1 (ru) 2004-10-28
EP1395253A2 (en) 2004-03-10
JP2004529073A (ja) 2004-09-24
WO2002040006A3 (en) 2003-12-24
KR20030051812A (ko) 2003-06-25
PL366119A1 (en) 2005-01-24
HRP20030384A2 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
EA005029B1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
US6184222B1 (en) Treatment of conduct disorder
KR20010024218A (ko) 반항성 장애의 치료
SK5422003A3 (en) Treatment of anxiety disorders
US20080200555A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
EP1458368B1 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
SK12812002A3 (sk) Spôsob liečenia psoriázy
US20040034106A1 (en) Treatment of anxiety disorders
ZA200303738B (en) Treatment of anxiety disorders.
RU2238084C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
HUT71466A (en) Pharmaceutical compositions for inhibition of obsessive-compulsive and consumptive disorders containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
US4443479A (en) Pharmaceutical methods and compositions using parabenzoquinone
US4522830A (en) Pharmaceutical methods using parabenzoquinone to treat muscle spasms
MXPA00002837A (en) Treatment of oppositional defiant disorder
MXPA00002829A (en) Treatment of conduct disorder

Legal Events

Date Code Title Description
FC9A Refused patent application